NCT00462670已完成3 期
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 110
- 主要终点
- Body Weight (Amount of Change)
研究概览
简要总结
To evaluate the efficacy and safety of 7-day repeated oral administration of OPC-41061 15 mg or placebo in congestive heart failure (CHF) patients with extracellular volume expansion despite the use of a conventional diuretic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects receiving one of the following diuretic treatments (including subjects scheduled to start treatment during the run-in observation period, 1)A loop diuretic at a daily dosage equivalent to 40 mg or more of furosemide, 2)Concomitant administration of a loop diuretic and a thiazide diuretic (at any doses), 3)Concomitant administration of a loop diuretic and an anti-aldosterone drug (at any doses)
- •CHF patients with lower limb edema, jugular venous distention, or pulmonary congestion due to extracellular volume expansion Patients with pulmonary congestion can be enrolled if pulmonary congestion is confirmed on chest x-ray taken within 14 days prior to the screening examination.
- •Male or female subjects age 20 or older and younger than 85 (at time of informed consent)
- •Subjects who are able to stay at the study site from the day before the start of the run-in observation period until completion of postdosing examination 2 (7 to 10 days after final study drug administration)
- •Subjects capable of giving informed consent to participate in the study of their own free will
排除标准
- •Subjects with acute heart failure
- •Subjects with an assisted circulation device
- •Subjects with any of the following complications or symptoms: (1)Suspected decrease in circulatory blood flow, (2)Hypertrophic cardiomyopathy (other than dilated phase), (3)Cardiac valve disease with significant heart valve stenosis, (4)Hepatic coma
- •Subjects who develop acute myocardial infarction within 30 days prior to the screening examination
- •Subjects with a definite diagnosis of active myocarditis or amyloid cardiomyopathy
- •Subjects with any of the following complications or symptoms: (1)Diabetes mellitus with poorly controlled blood glucose, (2)Anuria, (3)Urination impaired due to urinary tract stricture, urinary calculus, tumor in urinary tract, or other cause
- •Subjects with a history of any of the following diseases: (1)Sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination in patients without an implanted defibrillator, (2)Cerebrovascular disorder within 6 months prior to the screening examination (other than asymptomatic cerebral infarction), (3)Hypersensitivity or idiosyncratic reaction to benzazepine derivatives such as mozavaptan hydrochloride or benazepril hydrochloride.
- •Subjects who are obese [body mass index (BMI, body weight (kg)/height (m)2 exceeding 35]
- •Patients with supine systolic blood pressure exceeding 90 mmHg
- •Subjects with any of following abnormal laboratory values: (1)Total bilirubin exceeding 3.0 mg/dL, (2)serum creatinine exceeding 3.0 mg/dL, (3)serum sodium exceeding 147 mEq/L, (4)serum potassium exceeding 5.5 mEq/L
- •Patients who are unable to take oral medication
- •Female subjects who are pregnant, possibly pregnant, or lactating, or who plan to become pregnant
- •Subjects who received any investigational drug other than OPC-41061 within 30 days prior to the screening examination
- •Subjects who previously participated in this or any other study of OPC-41061 and received OPC-41061
- •Subjects otherwise judged by the investigator or subinvestigator to be inappropriate for inclusion in the study
研究组 & 干预措施
1
Placebo Comparator
0mg
干预措施: OPC-41061(Tolvaptan) (Drug)
2
Experimental
15mg OPC-41061
干预措施: OPC-41061(Tolvaptan) (Drug)
结局指标
主要结局
Body Weight (Amount of Change)
时间窗: baseline, Day 7 or at the time of final trial drug administration
Change in body weight from baseline at the time of final trial drug administration
次要结局
- Body Weight (Percent Change)(baseline, Day 7 or at the time of final trial drug administration)
研究者
相似试验
已完成
2 期
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or HemodiafiltrationChronic Renal FailureNCT02331680Otsuka Pharmaceutical Co., Ltd.124
已完成
2 期
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]Autosomal Dominant Polycystic Kidney DiseaseNCT00841568Otsuka Pharmaceutical Co., Ltd.17
已完成
3 期
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)Cardiac EdemaNCT00544869Otsuka Pharmaceutical Co., Ltd.52
已完成
3 期
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic EdemaCirrhosisNCT01114828Otsuka Pharmaceutical Co., Ltd.40
未知
3 期
A double-blind, placebo-controlled study of OPC-41061 in the treatment of cardiac edema (congestive heart failure)JPRN-jRCT2080220391Otsuka Pharmaceutical Co., Ltd.